CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

被引:111
作者
García-Martín, E
Martínez, C
Pizarro, RM
García-Gamito, FJ
Gullsten, H
Raunio, H
Agúndez, JAG
机构
[1] Univ Extremadura, Sch Biol Sci, Dept Biochem, Badajoz, Spain
[2] Univ Extremadura, Sch Med, Dept Pharmacol, Badajoz, Spain
[3] Univ Extremadura, Sch Med, Dept Surg, Badajoz, Spain
[4] Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Helsinki, Finland
[5] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
关键词
D O I
10.1067/mcp.2002.121371
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Our objective was to evaluate the presence of CYP3A4 gene variants in white individuals with low CYP3A4 enzyme activity. Methods: Persons with extremely low enzyme activity, either in vitro or in vivo, were selected in a panel of 97 healthy subjects. Genetic analyses for CYP3A4 variant alleles present in white subjects, including CYP3A4*1B, CYP3A4*2, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*8, CYP3A4*11, CYP3A4*12, and CYP3A4*13, were performed on genomic deoxyribonucleic acid from these subjects by amplification-restriction and sequencing. Results. With the exception of CYP3A4*1B, none of the variant alleles analyzed were present in 30 genes from persons with extremely low enzyme activity. CYP3214*1B was present in the population studied with an allele frequency of 5.5%. Nevertheless, the presence of CYP3A4*1B does not correlate with low enzyme activity, either in vivo or in vitro, in either heterozygosity or homozygosity. CYP3A4*2 was not identified in 290 genes from Spanish persons or in 70 genes from Finnish persons. Conclusions. Although the genetic component of the interindividual variability of CYP3A4 enzyme activity seems to be high, our findings do not support a key role for the variant alleles analyzed on the majority of white persons with low CYP3A4 activity This suggests the occurrence of as yet unknown mutations that affect CYP3A4 or other functionally related genes.
引用
收藏
页码:196 / 204
页数:9
相关论文
共 35 条
[1]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]   Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 [J].
Ball, SE ;
Scatina, JA ;
Kao, J ;
Ferron, GM ;
Fruncillo, R ;
Mayer, P ;
Weinryb, I ;
Guida, M ;
Hopkins, PJ ;
Warner, N ;
Hall, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) :288-294
[3]  
Barwick JL, 1996, MOL PHARMACOL, V50, P10
[4]  
Cavalli SA, 2001, CLIN CHEM, V47, P348
[5]   Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity [J].
Ducharme, J ;
Abdullah, S ;
Wainer, IW .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 678 (01) :113-128
[6]   Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients [J].
Eap, CB ;
Bender, S ;
Gastpar, M ;
Fischer, W ;
Haarmann, C ;
Powell, K ;
Jonzier-Perey, M ;
Cochard, N ;
Baumann, P .
THERAPEUTIC DRUG MONITORING, 2000, 22 (02) :209-214
[7]   Identification and functional characterization of eight CYP3A4 protein variants [J].
Eiselt, R ;
Domanski, TL ;
Zibat, A ;
Mueller, R ;
Presecan-Siedel, E ;
Hustert, E ;
Zanger, UM ;
Brockmoller, J ;
Klenk, HP ;
Meyer, UA ;
Khan, KK ;
He, YA ;
Halpert, JR ;
Wojnowski, L .
PHARMACOGENETICS, 2001, 11 (05) :447-458
[8]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[9]   Association of CYP3A4 genotype with treatment-related leukemia [J].
Felix, CA ;
Walker, AH ;
Lange, BJ ;
Williams, TM ;
Winick, NJ ;
Cheung, NKV ;
Lovett, BD ;
Nowell, PC ;
Blair, IA ;
Rebbeck, TR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13176-13181
[10]   AMINOPYRINE N-DEMETHYLASE ACTIVITY IN HUMAN LIVER-MICROSOMES [J].
GARCIAAGUNDEZ, JA ;
LUENGO, A ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (05) :490-495